PURPOSE: We hypothesized that administration of the anti-inflammatory peroxisomal proliferator-activated receptor gamma (PPARgamma) agonist pioglitazone (Pio) to adult male rats would inhibit radiation-induced cognitive impairment. METHODS AND MATERIALS: Young adult male F344 rats received one of the following: (1) fractionated whole brain irradiation (WBI); 40 or 45 Gy gamma-rays in 4 or 4.5 weeks, respectively, two fractions per week and normal diet; (2) sham-irradiation and normal diet; (3) WBI plus Pio (120 ppm) before, during, and for 4 or 54 weeks postirradiation; (4) sham-irradiation plus Pio; or (5) WBI plus Pio starting 24h after completion of WBI. RESULTS: Administration of Pio before, during, and for 4 or 54 weeks after WBI prevented the radiation-induced cognitive impairment. Administration of Pio for 54 weeks starting after completion of fractionated WBI substantially but not significantly reduced the radiation-induced cognitive impairment. CONCLUSIONS: These findings offer the promise of improving the quality of life and increasing the therapeutic window for brain tumor patients.
PURPOSE: We hypothesized that administration of the anti-inflammatory peroxisomal proliferator-activated receptor gamma (PPARgamma) agonist pioglitazone (Pio) to adult male rats would inhibit radiation-induced cognitive impairment. METHODS AND MATERIALS: Young adult male F344 rats received one of the following: (1) fractionated whole brain irradiation (WBI); 40 or 45 Gy gamma-rays in 4 or 4.5 weeks, respectively, two fractions per week and normal diet; (2) sham-irradiation and normal diet; (3) WBI plus Pio (120 ppm) before, during, and for 4 or 54 weeks postirradiation; (4) sham-irradiation plus Pio; or (5) WBI plus Pio starting 24h after completion of WBI. RESULTS: Administration of Pio before, during, and for 4 or 54 weeks after WBI prevented the radiation-induced cognitive impairment. Administration of Pio for 54 weeks starting after completion of fractionated WBI substantially but not significantly reduced the radiation-induced cognitive impairment. CONCLUSIONS: These findings offer the promise of improving the quality of life and increasing the therapeutic window for brain tumorpatients.
Authors: Munjal M Acharya; Lori-Ann Christie; Mary L Lan; Erich Giedzinski; John R Fike; Susanna Rosi; Charles L Limoli Journal: Cancer Res Date: 2011-07-14 Impact factor: 12.701
Authors: Susanna Rosi; Marta Andres-Mach; Kelly M Fishman; William Levy; Ryan A Ferguson; John R Fike Journal: Cancer Res Date: 2008-12-01 Impact factor: 12.701
Authors: Dana Greene-Schloesser; Valerie Payne; Ann M Peiffer; Fang-Chi Hsu; David R Riddle; Weiling Zhao; Michael D Chan; Linda Metheny-Barlow; Mike E Robbins Journal: Radiat Res Date: 2014-01-07 Impact factor: 2.841